As CBD Journal reported back in June, the FDA has approved the use of a CBD-based drug called Epidiolex for the treatment of two of the hardest-to-treat forms of epilepsy, Lennox-Gastaut syndrome, and Dravet syndrome. According to a story in the New York Times, makers of the drug, British-based GW Pharmaceuticals, says the drug will cost roughly $32,500 per year.
Following a public comment period initiated by the United States Food & Drug Administration on behalf of the United Nations and the World Health Organization on the potential medical benefits of Cannabidiol, or CBD, and sixteen other drug substances, the WHO plans to meet in Geneva this November "to review the substances and begin work on potential recommendations to the United Nations Secretary-General." This assembly will be the 39th Meeting of the WHO's Expert Committee on
On a request from the United Nations, which is exploring how to categorize CBD and various other drugs according to the 1971 Convention on Psychotropic Substances, the Food and Drug Administration has issued a public request for comment on the positives and Negatives of CBD. In the request the FDA acknowledged CBD's medical potential: